DTIL, US74019P2074

Precision BioSciences announces HBV talk: Precision BioSciences stock gains 1.79 percent

Published on 10/08/2026 at 16:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Precision BioSciences stock costs EUR 5.68 on October 8, 2026. That is plus 1.79 percent versus EUR 5.58, with HBV data on November 8, 2026.

Precision BioSciences announced a late-breaking PBGENE-HBV presentation at AASLD on October 8, 2026.
The company reported 16 patients treated across 38 administrations in its hepatitis B program.
The Lang & Schwarz price was EUR 5.68 on October 8, 2026, plus 1.79 percent versus EUR 5.58.

DTIL, US74019P2074, Illustration mit AI erstellt.

Precision BioSciences (ISIN US74019P2074) was trading at EUR 5.68 at Lang & Schwarz on October 8, 2026 at 4:11 p.m. CEST, up 1.79 percent versus EUR 5.58. According to Precision BioSciences on October 8, 2026, the company had been selected for a late-breaking oral presentation on PBGENE-HBV at The Liver Meeting 2026. The presentation is scheduled for November 8, 2026.

Three clinical milestones

On August 24, 2026, Precision said its first patient had been dosed in the Phase 1/2 FUNCTION-DMD trial, according to Inside Precision Medicine. On September 16, 2026, management said at the H.C. Wainwright conference that PBGENE-HBV had treated 16 patients across 38 administrations and that second-quarter cash of USD 112 million supported a runway through 2028, as Investing.com reported. On October 8, 2026, Precision announced the AASLD presentation for November 8, 2026, according to Precision BioSciences.

What does the HBV presentation add?

The event gives investors a defined date for the next clinical communication on PBGENE-HBV. Precision says the program is being evaluated in the Phase 1 ELIMINATE-B trial and is designed to target cccDNA, the source of viral replication in chronic hepatitis B, according to the October 8 release.

The September 16 update supplies the operating benchmark: 16 patients and 38 administrations. It also identifies the financial counterweight, with USD 112 million in cash at the end of the second quarter of 2026 and a stated runway through 2028. The two figures connect clinical progress with funding duration rather than presenting the November event as a standalone date.

Next dates for DTIL

The next clinical date is November 8, 2026, when the PBGENE-HBV presentation is scheduled at The Liver Meeting 2026, according to Precision BioSciences. The next earnings date is November 10, 2026, listed by Investing.com.

Stock moves with the clinical calendar

The Lang & Schwarz quote places the stock at EUR 5.68 on October 8, 2026 at 4:11 p.m. CEST, plus 1.79 percent versus the EUR 5.58 prior close. The same-day move is modest beside the program milestones, so the November presentation and the November earnings date remain the clearer near-term reference points.

The further course of trading is shown by the continuously updated real-time quote of Precision BioSciences stock.